A5068351536- Multiple Sclerosis Research Studies
- Polyomavirus and related diseases
- SARS-CoV-2 and COVID-19 Research
- Peripheral Neuropathies and Disorders
- Acute Lymphoblastic Leukemia research
- Plant Virus Research Studies
- Long-Term Effects of COVID-19
- RNA Interference and Gene Delivery
- CNS Lymphoma Diagnosis and Treatment
- Systemic Sclerosis and Related Diseases
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Retinal and Optic Conditions
- Urinary Bladder and Prostate Research
- Chronic Myeloid Leukemia Treatments
- Systemic Lupus Erythematosus Research
- Mycobacterium research and diagnosis
- Parvovirus B19 Infection Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Viral Infections and Immunology Research
- COVID-19 Clinical Research Studies
- Autoimmune and Inflammatory Disorders
- Rheumatoid Arthritis Research and Therapies
- Dermatological and Skeletal Disorders
- Hereditary Neurological Disorders
Jersey Shore University Medical Center
2023-2025
Hackensack Meridian Health
2024
New York University
2015-2024
Rocky Mountain Multiple Sclerosis Clinic
2019-2024
NeuroRx Research (Canada)
2024
Multiple Sclerosis Center Of Northeastern New York
2014-2023
NYU Langone Health
2015-2022
Hinge Health
2020-2021
Biogen (United States)
2019-2021
Washington University in St. Louis
2021
To use the large dataset from Tysabri Outreach: Unified Commitment to Health (TOUCH) program compare progressive multifocal leukoencephalopathy (PML) risk with natalizumab extended interval dosing (EID) vs standard (SID) in patients multiple sclerosis (MS).This retrospective cohort study included anti-JC virus antibody-positive (n = 35,521) TOUCH database as of June 1, 2017. The effect EID on PML was evaluated 3 planned analyses using Kaplan-Meier methods stratified by prior...
To report outcomes on patients with multiple sclerosis (MS) and related disorders coronavirus disease 2019 (COVID-19) illness.
<h3>Background</h3> Natalizumab (NTZ), a monoclonal antibody to human α<sub>4</sub>β<sub>1</sub>/β<sub>7</sub> integrin, is an effective therapy for multiple sclerosis (MS), albeit associated with progressive multifocal leukoencephalopathy (PML). Clinicians have been extending the dose of infusions hypothesis reducing PML risk. The aim study evaluate clinical consequences NTZ frequency infusion up 8 weeks 5 days. <h3>Methods</h3> A retrospective chart review in 9 MS centres was performed...
To compare clinical and imaging features of multiple sclerosis (MS) severity between Black Americans (BAs) White (WAs) to evaluate the role socioeconomic status.We compared BA WA participants in Multiple Sclerosis Partners Advancing Technology Health Solutions (MS PATHS) cohort with respect MS characteristics, including self-reported disability, objective neurologic function assessments, quantitative brain MRI measurements, after covariate adjustment (including education level, employment,...
The objective of this study was to determine the impact multiple sclerosis (MS) disease-modifying therapies (DMTs) on development cellular and humoral immunity severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection.Patients with MS aged 18 60 years were evaluated for anti-nucleocapsid anti-Spike receptor-binding domain (RBD) antibody electro-chemiluminescence immunoassay; responses Spike protein, RBD, N-terminal multiepitope bead-based immunoassays (MBI); live virus...
Fatigue is one of the most common and distressing symptoms among persons with multiple sclerosis (pwMS).The aim this study to evaluate fatigue as a predictor for disease worsening pwMS.In retrospective cohort New York State MS Consortium (NYSMSC) registry, patients reporting moderate-to-severe at enrollment (n = 2714) were frequency matched less-fatigued subjects on age, baseline Kurtzke Expanded Disability Status Scale (EDSS), duration, phenotype. Change from patient-reported outcomes...
Background: Extended interval dosing (EID; average approximately every 6 weeks) of natalizumab is associated with significantly lower risk progressive multifocal leukoencephalopathy than standard (SID; 4 in patients relapsing-remitting multiple sclerosis (MS). Real-world studies, though limited, suggest that effectiveness generally maintained who switch to EID after initiation stable treatment SID. MS PATHS (Multiple Sclerosis Partners Advancing Technology and Health Solutions) a...
Background: People with MS (PwMS) and related conditions treated anti-CD20 S1P modulating therapies exhibit attenuated immune responses to SARS-CoV-2 vaccines. It remains unclear whether humoral/T-cell are valid surrogates for postvaccine immunity. Objective: To characterize COVID-19 vaccine-breakthrough infections in this population. Methods: We conducted a prospective multicenter cohort study of PwMS CNS autoimmune confirmed breakthrough infections. Postvaccination antibody response,...
A 66-year-old man with hypertension presented right-sided numbness and slurred speech. MRI revealed a large left frontoparietal area of T2-weighted hyperintensity focus central enhancement (figure, B). The patient's symptoms self-resolved within weeks. Over the next 2 years, he experienced multiple relapses including encephalopathy characterized by headache motor aphasia sudden incomplete hearing loss. All except loss were transient, improved IV methylprednisolone, accompanied new T2 lesions...
To determine if the concentration and saturation of natalizumab (NTZ) administration at extended interval dosing (EID; every 5-8 weeks) over 18 months is able to be maintained in range considered adequate sustain clinical efficacy NTZ.In a cross-sectional assessment patients with multiple sclerosis (MS) who received standard (every 4 or EID, serum NTZ concentrations were measured using ELISA, α4-integrin receptor saturations analyzed via cytometry, blood samples obtained trough...
ObjectiveTo determine outcomes of COVID-19 in patients with Multiple Sclerosis (MS) and related conditions, to predictors these outcomes.MethodsThis was a multicenter, observational cohort study MS or CNS autoimmune disorders who developed confirmed highly suspected infection from 2/1/2020 12/31/2020.Main outcome measureThe primary measure hospitalization status due COVID-19. Severity measured using 4-point ordinal scale: 1. home care; 2. without mechanical ventilation; 3. ventilation, 4....
Dimethyl fumarate (DMF) was approved by the US Food and Drug Administration (FDA) for treatment of relapsing-remitting multiple sclerosis (RRMS) based on two phase III randomized clinical trials (RCTs). There were not enough non-White patients enrolled in these RCTs to allow subgroup analysis race. Efficacy tolerability DMF therapy across various racial groups is unknown.Retrospective chart review performed all with RRMS who started tertiary (MS) clinics. compared three self-identified...
<h3>Background</h3> Patients with biopsy-proven systemic sarcoidosis who develop a chronic CNS disorder are often presumed to have neurosarcoidosis (NS), however, the possibility of comorbid neurologic disease, such as MS, must be considered if presentation and course not typical for NS. <h3>Methods</h3> Retrospective chart review across 4 academic MS centers was undertaken identify patients diagnosis (2017 McDonald criteria) biopsy-confirmed extraneural sarcoidosis. Data were abstracted...
To update the assessment of PML risk with natalizumab EID in comparison Q4W dosing using TOUCH data as June 30, 2023.
Following NOVA (part 1) and the approval of subcutaneous (SC) route administration natalizumab by European Medicines Agency, an extension phase IIIb study 2) was initiated to collect patient preference data for SC versus intravenous (IV) dosing in patients receiving every-6-week (Q6W) natalizumab. This performed evaluate IV explore efficacy, safety, pharmacology characteristics both routes administration. In part 2, participants received (Tysabri®) 300 mg via infusion Q6W 36 weeks then were...
Exposure to natalizumab, an efficacious treatment for relapsing-remitting multiple sclerosis (RRMS), is associated with increased risk of progressive multifocal leukoencephalopathy (PML). Compared every-4-week (Q4W) dosing, extended-interval dosing natalizumab decreased PML. Clinical efficacy was maintained in the majority patients switched every-6-week (Q6W) phase 3b NOVA clinical trial. In this article, we report pharmacokinetics (PK) and pharmacodynamics (PD) Q6W vs Q4W NOVA.